Email |

King Pharma ends Skelaxin patent suit; CorePharma will get generic rights

Published January 11th, 2008 | 0 Comments

King Pharmaceuticals Inc. said Tuesday it terminated its patent infringement lawsuit against CorePharma LLC over the muscle relaxant drug Skelaxin, and granted CorePharma certain generic rights under a product agreement.

In a filing with the Securities and Exchange Commission, Bristol, Tenn.-based King said it signed a metaxalone 800 mg product agreement on Jan. 2 granting CorePharma certain rights for an authorized generic version of the company's 800 mg Skelaxin product.

King also said ending the lawsuit terminated all of Cores counterclaims without prejudice.

Core, Eon Labs Inc. and Mutual Pharmaceutical Co. Inc. had each filed with the Food and Drug Administration seeking to market a generic version of Skelaxin 400 mg tablets. Additionally, Eon Labs had sought permission to market a generic 800mg version.

Discuss This Story

Be the first to comment: Sign In or Create Profile .

To comment, you must register.

Comments are the sole responsibility of the registered user participating in online discussions. You agree not to post comments off topic, abusive, obscene, defamatory, vulgar, threatening or an invasion of privacy. Violators may be banned.

Click here to review our complete user agreement.

Times-News Online on Facebook

Featured Blogger

Favorite Films of the Past Decade...?!?!?

By Jared Bentley - 12-27-2009

The end of the year is traditionally a time for lists, at least for the sort of people who make lists (And sadly, I find myself being one of those peo...

Read Post | Comments (10)